Sermorelin vs tesamorelin: which growth-hormone peptide is the right tool for you

A clinic hands you two names off the same shelf. Sermorelin on one line, tesamorelin on the next. Both do the same clever thing: they ask your own pituitary to make more of your own growth hormone, in the natural pulses it has always used, instead of piping the hormone in from outside. That is the part worth getting excited about, and it is genuinely exciting.

Then the paperwork splits them apart. Tesamorelin is still an approved drug. Sermorelin used to be one — twice — and lost both approvals for business reasons. Same receptor, same upstream lever, two completely different regulatory files. Which one is the better tool comes down to what you are actually chasing. Let’s put them side by side and answer that plainly.

What each one could actually do for you

Start with the thing they share, because it is the reason either one is on the menu at all.

As you move through your forties, your growth-hormone output doesn’t switch off. It idles down. The nightly pulses get smaller. Sermorelin and tesamorelin both nudge the gland that makes GH to fire a little more like it did a decade ago — working with your own rhythm instead of overriding it. Deeper sleep, quicker recovery between hard sessions, a slow shift in body composition: the things people actually chase all sit downstream of that dial. Both molecules turn it.

Where they part ways is what each one is best aimed at.

Tesamorelin has a target it can prove it hits: the deep fat. Not the soft layer you can pinch — the visceral kind, packed behind the abdominal wall and wrapped around your organs, the fat that drives rising triglycerides and creeping insulin resistance. In a real trial, tesamorelin brought that deep fat down and the bloodwork moved with it. If your worry is a thickening waist and numbers sliding the wrong way, that is the one with human evidence behind the claim.

Sermorelin is the gentler, older option — the GH-axis nudge with an actual FDA past and an easier route to the pharmacy counter. It was a real prescription drug. Longevity clinics that still compound it lean on that pedigree, and on paper they have a point. What it doesn’t have is a trial in healthy men your age showing the dial-turn changes anything you’d feel. Hold that thought; it matters below.

So the honest early frame: tesamorelin for the deep-fat and metabolic case with the stronger file, sermorelin for the gentle GH-axis nudge with the friendlier supply. Both are real bets. Neither is a clean one. Here is why the underlying biology earns the interest before we get to the catches.

Same receptor, different chemistry

Both molecules are copies of one signal your own brain already makes.

That signal is GHRH. It travels to the pituitary — a pea-sized gland tucked behind your eyes — and tells it to release a pulse of growth hormone. Native GHRH is 44 building blocks long. Sermorelin and tesamorelin both flip that same switch, and both leave the actual GH release to your own gland.

Sermorelin is the first 29 of those building blocks — the working end that grabs the receptor, with no chemical decoration. That keeps it simple. It also keeps it short-lived: the body clears the bare fragment in minutes, which is why the old dosing schedule was a nightly injection.

Tesamorelin is the full 44-residue signal with one small chemical group bolted onto one end. That single tweak blocks the enzyme that would otherwise chop the molecule apart, so it lingers long enough for once-daily dosing to do the job. Minutes versus long-enough-to-matter — that gap is exactly what made an FDA drug application possible for tesamorelin and not for sermorelin.

Same lever. Same downstream pulse of your own GH. Different chemistry, different staying power, and, as it turned out, very different fates at the FDA.

The spec sheet, side by side

The marketing flattens these two into one idea — two GHRH peptides — when the details underneath run in different directions. Pull the structural and regulatory facts into a single frame.

Two takeaways from that sheet. The mechanism column is genuinely identical — both molecules pull the same upstream lever on the same gland. The FDA column is genuinely opposite. One molecule had two approvals and lost both for business reasons; the other has one and is still on the shelf, in a population almost no buyer belongs to.

What the human files actually hold

This is where the two peptides stop looking like twins.

Take strict sermorelin first — GHRH (1-29), the unmodified fragment. Its published human record in healthy adults is small and old. Vittone and colleagues, in 1997 (Metabolism), gave nightly injections to healthy elderly men and watched growth hormone and IGF-1 climb. The longer-run work is Khorram, Laughlin and Yen, also 1997 (JCEM), in age-advanced men and women. The dial moved there too. Two papers, one lab, one year, in older adults, measuring hormone numbers rather than anything a man would feel.

Now a detail the brochures quietly drop. That second Khorram study didn’t run on strict sermorelin. It used a stabilised cousin — [Nle27]GHRH (1-29), a swap at one position that makes the molecule last longer in the blood. Close analog, not the exact thing. The 1990s GHRH literature is full of this, and marketing files the analog under the sermorelin name without the asterisk. The honest label is a stabilised sermorelin analog.

There is one more borrowed footnote, and it’s the big one. The cognition result the sermorelin longevity case leans on hardest — Baker and colleagues, 2012 (Archives of Neurology), a real randomised trial in 152 older adults, cognition improving at P equals 0.03 — didn’t test sermorelin at all. It tested tesamorelin. The paper gets mis-attributed to sermorelin constantly. The clearest GHRH-cognition signal in print belongs to the other molecule on this page.

Tesamorelin’s file is a different order of thing. The pivotal trial is Falutz and colleagues, 2007, in the New England Journal of Medicine: 412 HIV-infected adults with abdominal-fat accumulation, 26 weeks, deep visceral fat falling about 15 percent on tesamorelin while it rose about 5 percent on placebo, with triglycerides and the cholesterol ratio improving. That trial earned NDA 022505 and put Egrifta on the market. Beyond it sits Makimura and colleagues, 2012 (JCEM) — 60 non-HIV abdominally obese adults with reduced GH, followed a full year, the deep fat again falling selectively while the metabolic markers improved without upsetting blood sugar. Add the Baker cognition result and its biomarker follow-up by Winston and colleagues in 2018, which moved some synaptic markers but left amyloid and tau unchanged.

Lay the two files in one frame.

Read those rows straight. On strict sermorelin, the human file in healthy adults is two small biomarker papers from one lab in 1997 — and one of them ran on the stabilised cousin, not the exact molecule. On tesamorelin, it’s a real Phase III in one disease population, a small non-HIV trial, and a single positive cognition result. None replicated outside its original group. So the GHRH peptide with the deeper published human evidence is tesamorelin, on every row where a comparison is even possible. That is not the order the brochures tend to present it in.

Now hold the excitement to the honest line. Not one of those tesamorelin trials enrolled a healthy man in his forties chasing longevity. The Phase III was HIV lipodystrophy by design. Makimura widened the window only to non-HIV adults whose GH was already low. For the buyer’s real population, both molecules run on mechanism plus extrapolation — tesamorelin simply extrapolates from firmer ground.

Where the regulators stand this summer

Neither peptide is waiting on the July vote, and for once that is the simple part.

Neither sermorelin nor tesamorelin is on the FDA Pharmacy Compounding Advisory Committee’s July 23–24, 2026 docket, and neither is on the second-wave list scheduled before the end of February 2027. That docket exists to weigh unapproved bulk substances for compounding. Both molecules sit outside it — for opposite reasons that trace straight back to the FDA files above. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is.

Sermorelin’s drug-application lane is empty. Geref left the market in 2008 and the FDA formally withdrew both approvals in June 2009, for commercial reasons — so the active ingredient stays available through Section 503A compounding. Nothing to bump up against. Tesamorelin’s lane is occupied. Egrifta is on the market right now, which means the rules sharply limit compounding a copy of the same active ingredient. That’s the same wall PT-141 runs into.

So here’s the quiet trade sitting under the two prescriptions. The molecule with more evidence is the harder one to get through compounding. The molecule with less evidence is the easier one. That is rarely what decides which name lands on the pad.

Anti-doping is the clean line on both. Sermorelin and tesamorelin are both growth-hormone-releasing factors, and WADA prohibits that entire class under S2, in and out of competition. If you compete, treat either as banned and check the current code on the day. Domestic legality and competition eligibility are separate questions, and they stay separate after July.

So which one, if you’re actually deciding

Two honest answers, and they run in different directions.

Chasing the deep-fat and metabolic effect, and you want the option with real human evidence behind the claim? That’s tesamorelin. A genuine Phase III, a small non-HIV trial that widened the picture, the strongest file in the class. The catch: those trials were run in patients you almost certainly aren’t, and the drug’s approved status keeps compounded supply under enforcement pressure sermorelin escapes.

Want the gentler GH-axis nudge, the one with an actual FDA pedigree and an open compounding route? That’s sermorelin. The Geref history is real, the withdrawal was about business rather than safety, and the pharmacy door stays open. The catch: the strict-molecule human evidence in healthy adults is two papers from 1997, and the cognition trial everyone quotes for it was tesamorelin.

Neither answer is clean. The one with the deeper file is harder to obtain; the one that’s easy to obtain has the thinner file. For plenty of buyers the real deciding factor isn’t the evidence at all — it’s which compounding lane their clinic prefers to work in.

Two files, one prescription pad

The GHRH-class choice is the one spot on the longevity menu where the evidence question and the supply question pull against each other, on the same prescription pad. Sermorelin is easy to get and thin on proof for the people buying it. Tesamorelin is hard to compound and carries the deeper file. A brochure will sell you either without mentioning the trade. A physician who has actually read both files won’t.

That reading is the entire point of what we’re building. Wolverine Health is being set up so the doctor choosing between these two decides on the evidence and your real goal — the deep-fat and metabolic case versus the gentle GH-axis nudge — not on whichever molecule the pharmacy finds easiest to stock. Physician-supervised protocols, US-licensed compounding, an assay on every batch. For these two in particular the right call is sometimes sermorelin, sometimes tesamorelin, and sometimes neither — and you deserve that answer from someone who read the trials, not someone reading a price list.

We can’t hand you that answer until the rules let the service open, which is the plain reason it hasn’t yet. Tell us where to reach you, and the day a doctor can finally weigh these two files properly on your behalf, you’ll be first to hear it.